HEM Pharma Invests 2.18 Billion KRW in myLAB Analysis Service Automation, Expected to Boost Profitability and Shareholder Value
HEM Pharma has decided to invest 2.18 billion KRW approximately 41.84% of its equity in new facilities for full-process automation of its myLAB analysis service.
The investment was approved by the board with all three outside directors present, while the auditor was absent. The investment period runs from June 2026 to March 2027.
The automation equipment is expected to improve operational efficiency and service quality, positively impacting mid-to-long-term profitability. No new shares are issued, so no dilution of existing shareholder value.
[AI Summary]HEM Pharma is strengthening its myLAB analysis service competitiveness with a large automation investment equivalent to 41.84% of equity. As it is a facility investment without share issuance, there is no dilution concern, and efficiency gains are expected to boost profitability. The auditor's absence poses a minor governance risk, but board decision transparency is secured with outside director attendance.